IRIS UniCatt

De Cristofaro, Raimondo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.907
EU - Europa 4.530
AS - Asia 4.205
SA - Sud America 964
AF - Africa 119
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 14.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.784
SG - Singapore 1.992
DE - Germania 1.480
CN - Cina 1.142
SE - Svezia 814
BR - Brasile 808
UA - Ucraina 462
IT - Italia 430
FR - Francia 261
IE - Irlanda 233
GB - Regno Unito 229
VN - Vietnam 225
IN - India 205
FI - Finlandia 161
ID - Indonesia 161
PL - Polonia 152
RU - Federazione Russa 126
AR - Argentina 68
CA - Canada 66
HK - Hong Kong 66
TR - Turchia 65
JP - Giappone 57
BD - Bangladesh 50
IQ - Iraq 49
ZA - Sudafrica 42
KR - Corea 37
MX - Messico 35
NL - Olanda 35
BE - Belgio 25
EC - Ecuador 23
IR - Iran 21
AT - Austria 20
ES - Italia 17
UZ - Uzbekistan 17
CO - Colombia 16
SA - Arabia Saudita 15
AU - Australia 14
LT - Lituania 14
VE - Venezuela 14
KE - Kenya 13
MA - Marocco 13
PK - Pakistan 13
CI - Costa d'Avorio 12
EG - Egitto 12
CL - Cile 11
CZ - Repubblica Ceca 11
RO - Romania 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
UY - Uruguay 9
DZ - Algeria 8
IL - Israele 8
PY - Paraguay 8
CH - Svizzera 7
NP - Nepal 7
AL - Albania 6
JO - Giordania 6
KZ - Kazakistan 6
MK - Macedonia 6
KW - Kuwait 5
OM - Oman 5
PH - Filippine 5
CR - Costa Rica 4
EU - Europa 4
JM - Giamaica 4
KG - Kirghizistan 4
NO - Norvegia 4
PE - Perù 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
AZ - Azerbaigian 3
BG - Bulgaria 3
BH - Bahrain 3
BO - Bolivia 3
HN - Honduras 3
HU - Ungheria 3
LU - Lussemburgo 3
LV - Lettonia 3
MY - Malesia 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GR - Grecia 2
LK - Sri Lanka 2
PA - Panama 2
PR - Porto Rico 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CY - Cipro 1
Totale 14.732
Salva come PNG Salva come JPEG
Città #
Singapore 831
Chandler 657
Ashburn 564
Jacksonville 249
Dublin 224
Beijing 223
San Mateo 212
Nanjing 159
Jakarta 145
Wilmington 142
Los Angeles 136
Hefei 130
Warsaw 130
New York 124
Ann Arbor 112
Milan 108
Woodbridge 99
Boston 98
Munich 89
Dearborn 88
Houston 86
Chicago 83
Moscow 81
Fairfield 77
Ho Chi Minh City 73
Lawrence 71
Pune 71
Redwood City 71
Seattle 71
São Paulo 67
Nürnberg 65
Frankfurt am Main 56
Dallas 55
Hong Kong 55
Princeton 55
Cattolica 53
Hanoi 53
Nanchang 52
Marseille 45
Redmond 44
Rome 44
Tokyo 41
Helsinki 40
Buffalo 38
London 37
Izmir 36
Seoul 33
University Park 33
Bremen 32
Kent 32
Rio de Janeiro 32
Santa Clara 32
Hangzhou 30
Augusta 27
Kunming 27
Mountain View 25
Tianjin 25
Nuremberg 24
Turku 24
Boardman 22
Brussels 22
Changsha 22
Hyderabad 22
Norwalk 22
Orem 22
Johannesburg 21
Shenyang 21
Phoenix 20
Brooklyn 19
Baghdad 18
Detroit 18
Zhengzhou 18
Bareggio 17
Hebei 17
San Francisco 17
Shanghai 17
Denver 16
Jiaxing 16
Mexico City 16
Cambridge 15
Curitiba 15
Montreal 15
Toronto 15
Belo Horizonte 14
Brasília 14
Guangzhou 14
Kraków 14
Paris 14
Poplar 14
Stockholm 14
Tashkent 14
Guarulhos 13
Padova 13
Abidjan 12
Amsterdam 12
Chennai 12
Haiphong 12
Leawood 12
Nairobi 12
Salvador 12
Totale 7.081
Salva come PNG Salva come JPEG
Nome #
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 320
The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. 313
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 304
Pathogenesis Of Portal Vein Thrombosis In Liver Cirrhosis: The Role of the ADAMTS13/VWF Unbalance 270
Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets 205
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 174
The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress 168
Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. 167
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 158
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 147
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study 146
Kinetic study of von Willebrand factor self-aggregation induced by ristocetin 143
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 136
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle 135
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from adamts-13 134
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 134
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study 134
Effect of fibrinogen concentration on the velocity of platelet aggregation. 133
An old drug for a new application: carbazochrome-sodium-sulfonate in HHT 133
Evaluation of the thiobarbituric acid test (TBA test) properties for the determination of glycosylated hemoglobins by comparison with chromatography and isoelectrofocusing. 132
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 132
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains 131
β2-Glycoprotein I Binds Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 130
Congenital prothrombin deficiency: an update 125
Structural and funtional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib 124
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 121
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects 119
Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? 116
high performance liquid chromatography in protein sequence determination. 115
Hexopeptidase high performance liquid chromatography (HPLC) mapping and is application to peptide sequence strategies. 114
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. 114
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 112
PURIFICATION OF THE ISOLATED BETA-CHAIN OF ADULT HUMAN-HEMOGLOBIN FROM ITS POST-TRANSLATIONAL MODIFICATION 111
MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY 110
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 110
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis 109
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 109
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 109
SPONTANEOUS DEEP HEMATOMAS IN 2 PATIENTS WITH MYELOFIBROSIS - EVIDENCE OF PLATELET MEMBRANE GLYCOPROTEIN MODIFICATIONS 108
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives 108
Hemophilia A and von Willebrand deficiency: therapeutic implications 108
Another family with IGPS 107
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 107
Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience 107
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study 106
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 105
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 105
Immune toilerance by intermittent factor VIII boluses in two hemophilia A patients 104
Direct oral anticoagulants and therapeutic adherence: do not let your guard down 104
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. 103
β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions 103
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 102
Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors 100
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 99
The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. 99
Allosteric equilibria in the binding reaction of fibrinogen to platelets. 99
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism 98
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. 97
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 97
Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases 97
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 97
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 97
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 96
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 96
The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. 96
Ristocetin-induced self-aggregation of von Willebrand factor. 95
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 93
Thrombin interaction with platelet GpIB: role of the heparin binding domain. 92
Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients 91
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 91
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 90
Congenital prothrombin deficiency 90
Placental-derived PGI2 inhibits cord blood platelet function 89
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 89
Mechanochemistry of von Willebrand factor 89
Placental derived PGI2 inhibits cord platelet function:possible role of PGI in THR transient hyporeactivity of newborn platelets 88
Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA 88
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey 88
ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study 87
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 86
The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy 85
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 83
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 83
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 82
Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects. 82
Effects of coagulation factors on bone cells and consequences of their absence in haemophilia a patients 81
KINETIC ASPECTS OF RELEASE OF FIBRINOPEPTIDES AP AND AY BY HUMAN ALPHA-THROMBIN 81
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 81
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking 80
Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence? 79
INHIBITION OF FIBRINOGEN BINDING TO HUMAN-PLATELETS BY BLOCKAGE OF NA+/H+ EXCHANGE. 79
Mechanistic studies on ADAMTS13 catalysis. 79
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 79
Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels 79
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 78
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies 78
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 77
Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory? 77
Carbon monoxyde and oxygen binding to human hemoglobin F0. 76
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus 76
Totale 11.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021570 0 0 0 0 0 50 109 19 117 76 166 33
2021/20221.124 83 114 24 62 64 35 34 173 60 54 206 215
2022/20231.973 264 318 165 259 155 233 80 171 230 26 56 16
2023/20241.163 41 316 30 78 49 203 66 61 17 39 102 161
2024/20252.597 58 42 197 98 191 89 59 121 419 317 554 452
2025/20263.826 1.071 306 452 718 1.068 211 0 0 0 0 0 0
Totale 14.878